Growth BioPharma
Insatiable Appetite For Investment And Growth.
Transactions of unprecedented size and volume. Vital need and continuous drive to increase deal flow, scale and valuation. Locust Walk supports active, strategic asset acquisition and divestiture for companies in the growth-oriented biopharmaceutical sector.
Today’s environment presents unique opportunities and challenges for growth-oriented pharmaceutical companies. Over the past few years – fueled by an historically low cost of capital, opportunities for tax-advantaged foreign domiciles, and customer consolidation – a flurry of merger and acquisition activity has intensified into an accelerating stream of transactions.
Growth-oriented companies are often pursued as acquisition targets of other companies. Their best defense: Increasing scale and market valuation to stay beyond the reach of potential suitors and remain independent. For those that ultimately are acquired, bulking up can often increase deal value.
Locust Walk offers a unique blend of exclusivity, superior deal flow, depth of expertise, and breadth of service for the growth biopharma sector.
Our international team of seasoned industry executives delivers specific, relevant operating deal experience. We provide comprehensive and exclusive guidance and support on both the buy-side and the sell-side.
Buy-side Process
Sell-side Process
OVERVIEW
- Asset criteria development
- Opportunity screening
- Profile development
- Target outreach
- Due diligence
- Deal structuring and evaluation
- Contract negotiations
RESULTS
- Strategic fit
- Non-obvious opportunities
- Timely decision-making
- Transactability
- Immediate increase in shareholder value
OVERVIEW
- Business case development
- Targeted partner outreach
- Due diligence staging
- Deal structuring and evaluation
- Contract negotiations
RESULTS
- Data-driven approach
- Structured process
- Competitive tension and bidding
- Real-time negotiations
- Maximum deal value
Locust Walk offers a unique blend of exclusivity, superior deal flow, depth of expertise, and breadth of service for the growth biopharma sector.
Our international team of seasoned industry executives delivers specific, relevant operating deal experience. We provide comprehensive and exclusive guidance and support on both the buy-side and the sell-side.
Buy-side Process
OVERVIEW
- Asset criteria development
- Opportunity screening
- Profile development
- Target outreach
- Due diligence
- Deal structuring and evaluation
- Contract negotiations
Buy-side Process
RESULTS
- Strategic fit
- Non-obvious opportunities
- Timely decision-making
- Transactability
- Immediate increase in shareholder value
Sell-side Process
OVERVIEW
- Business case development
- Targeted partner outreach
- Due diligence staging
- Deal structuring and evaluation
- Contract negotiations
Sell-side Process
RESULTS
- Data-driven approach
- Structured process
- Competitive tension and bidding
- Real-time negotiations
- Maximum deal value
Locust Walk offers a unique blend of exclusivity, superior deal flow, depth of expertise, and breadth of service for the growth biopharma sector.
Our international team of seasoned industry executives delivers specific, relevant operating deal experience. We provide comprehensive and exclusive guidance and support on both the buy-side and the sell-side.
Buy-side Process
OVERVIEW
- Asset criteria development
- Opportunity screening
- Profile development
- Target outreach
- Due diligence
- Deal structuring and evaluation
- Contract negotiations
RESULTS
- Strategic fit
- Non-obvious opportunities
- Timely decision-making
- Transactability
- Immediate increase in shareholder value
Sell-side Process
OVERVIEW
- Business case development
- Targeted partner outreach
- Due diligence staging
- Deal structuring and evaluation
- Contract negotiations
RESULTS
- Data-driven approach
- Structured process
- Competitive tension and bidding
- Real-time negotiations
- Maximum deal value
Growth BioPharma Transaction Highlights
CLIENT: Strongbridge Biopharma
PARTNER: Antisense Therapeutics
TRANSACTION:
Buy-side licensing agreement for ALT1103 for Acromegaly
CLIENT: Otsuka
PARTNER: Proteus
TRANSACTION:
Worldwide License and Collaboration Agreement
CLIENT: Strongbridge Biopharma
PARTNER: Aspireo Pharmaceuticals
TRANSACTION:
Buy-side product acquisition of Somatoprim for Acromegaly
CLIENT: BioAlliance Pharma
PARTNER: Innocutis
TRANSACTION:
US Commercialization Agreement for Sitavig® (acyclovir mucoadhesive tablet)
CLIENT: InterMune
PARTNER: Vidara
TRANSACTION:
Actimmune Product Divestiture for $55M upfront plus 2 year royalty